Date: 2014-02-11
Type of information: Development agreement
Compound: AUNP12
Company: Aurigene (India) Pierre Fabre (France)
Therapeutic area: Cancer - Oncology
Type agreement: development
licensing
commercialisation
Action mechanism: peptide/immune checkpoint inhibitor. AUNP-12 is a branched 29-amino acid peptide sequence engineered from the PD-L1/ L2 binding domain of PD-1. This immune checkpoint modulator blocks the PD-1/PD-L1, PD-1/PD-L2 and PD-L1/CD80 pathways. AUNP-12 is highly effective in antagonizing PD-1 signaling, with desirable in vivo exposure upon subcutaneous dosing. It inhibits tumor growth and metastasis in preclinical models of cancer and is well tolerated with no overt toxicity at any of the tested doses.
Disease:
Details: * On February 11, 2014, Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, have announced that they have entered into a collaborative license, development and commercialization agreement granting Pierre Fabre global Worldwide rights (excluding India) to a new immune checkpoint modulator, AUNP-12. AUNP-12 offers a breakthrough mechanism of action in the PD-1 pathway compared to other molecules currently in development in the highly promising immune therapy cancer space. AUNP-12 will be in development for numerous cancer indications.Under the terms of this agreement, Aurigene will receive an upfront payment from Pierre Fabre. Aurigene will also receive additional milestone payments based upon the continued development, regulatory progresses and commercialization of AUNP-12.
Financial terms:
Latest news:
